The use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) has gained acceptance in managing diabetic and non-diabetic patients, thanks to its benefits in treating obesity and improving cardiovascular outcomes. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.